Longeveron (LGVN) Depreciation & Amortization (CF) (2020 - 2026)
Longeveron (LGVN) recorded quarterly Depreciation & Amortization (CF) of $252000.0 in Q1 2026, down 9.35% quarter-over-quarter from $278000.0 in Q4 2025, and down 40.14% on a YoY basis from $421000.0 in Q1 2025.
Longeveron (LGVN) Depreciation & Amortization (CF) (2020 - 2026) Analysis & Trends
Longeveron's Depreciation & Amortization (CF) history runs 7 years deep, the most recent figure standing at $252000.0 for Q1 2026.
- In Q1 2026, Depreciation & Amortization (CF) fell 40.14% year-over-year to $252000.0; the TTM figure through Mar 2026 stood at $1.1 million (down 6.21% YoY), while the FY2025 annual figure was $1.2 million, up 27.97% from the prior year.
- Depreciation & Amortization (CF) was $252000.0 for Q1 2026 at Longeveron, down from $278000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $421000.0 in Q1 2025 to a low of $188000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $251470.6 across 5 years, with a median of $240000.0 in 2022.
- The sharpest annual moves came in 2025 and 2026: Depreciation & Amortization (CF) jumped 67.06% in 2025, then tumbled 40.14% in 2026.
- A 5-year view of Depreciation & Amortization (CF) shows it stood at $236000.0 in 2022, then changed by 0.0% to $236000.0 in 2023, then grew by 2.54% to $242000.0 in 2024, then increased by 14.88% to $278000.0 in 2025, then declined by 9.35% to $252000.0 in 2026.
- The last three Depreciation & Amortization (CF) figures came in at $252000.0 (Q1 2026), $278000.0 (Q4 2025), and $264000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | 1,395.22 |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1,330.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 55.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 429,663.65 |
| 10 | Longeveron | 20.35 Bn | 20.33 Bn | 264,000.00 | 252,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 252,000.00 |
| Mar 31, 2026 | 252,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Dec 31, 2025 | 278,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Sep 30, 2025 | 264,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Jun 30, 2025 | 263,000.00 |
| Mar 31, 2025 | 421,000.00 |
| Mar 31, 2025 | 421,000.00 |
| Dec 31, 2024 | 242,000.00 |
| Dec 31, 2024 | 242,000.00 |
| Sep 30, 2024 | 235,000.00 |
| Sep 30, 2024 | 235,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Jun 30, 2024 | 229,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Mar 31, 2024 | 252,000.00 |
| Dec 31, 2023 | 236,000.00 |
| Dec 31, 2023 | 236,000.00 |